OvaScience Inc. (OVAS) Stock Rating Upgraded by Zacks Investment Research
OvaScience Inc. (NASDAQ:OVAS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday. The brokerage presently has a $3.75 price objective on the stock. Zacks Investment Research’s price objective points to a potential upside of 5.63% from the stock’s previous close.
According to Zacks, “OvaScience, Inc. is a life science company focused on the discovery, development and commercialization of new treatments for infertility. Its product includes Augment for the treatment of infertility and Ova Ture used in the creation of mature fertilizable eggs. Ova Science, Inc. is headquartered in Cambridge, Massachusetts. “
A number of other research analysts also recently commented on OVAS. Credit Suisse Group AG restated a “sell” rating on shares of OvaScience in a research note on Tuesday, July 12th. JPMorgan Chase & Co. lowered their target price on OvaScience from $9.00 to $8.00 and set a “neutral” rating on the stock in a research note on Friday, August 5th. JMP Securities reiterated a “neutral” rating on shares of OvaScience in a research note on Wednesday, August 10th. Finally, HC Wainwright reiterated a “buy” rating on shares of OvaScience in a research note on Sunday, November 6th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $8.52.
OvaScience (NASDAQ:OVAS) opened at 3.55 on Wednesday. OvaScience has a 12 month low of $3.39 and a 12 month high of $11.66. The stock has a 50 day moving average price of $6.16 and a 200 day moving average price of $6.39. The firm’s market cap is $126.41 million.
OvaScience (NASDAQ:OVAS) last issued its earnings results on Thursday, November 3rd. The company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.08. OvaScience had a negative return on equity of 62.66% and a negative net margin of 11,642.67%. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.25 million. During the same quarter in the previous year, the company posted ($0.66) earnings per share. The business’s quarterly revenue was down 73.3% compared to the same quarter last year. On average, equities analysts expect that OvaScience will post ($2.64) earnings per share for the current fiscal year.
Several institutional investors have recently bought and sold shares of OVAS. JPMorgan Chase & Co. boosted its position in OvaScience by 2.8% in the first quarter. JPMorgan Chase & Co. now owns 341,789 shares of the company’s stock valued at $3,243,000 after buying an additional 9,350 shares in the last quarter. Orbis Allan Gray Ltd acquired a new position in OvaScience during the first quarter valued at $19,839,000. Trellus Management Company LLC acquired a new position in OvaScience during the second quarter valued at $208,000. Stoneridge Investment Partners LLC boosted its position in OvaScience by 120.4% in the second quarter. Stoneridge Investment Partners LLC now owns 49,960 shares of the company’s stock valued at $260,000 after buying an additional 27,291 shares in the last quarter. Finally, FNY Managed Accounts LLC acquired a new position in OvaScience during the second quarter valued at $208,000. 80.59% of the stock is owned by institutional investors and hedge funds.
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
Receive News & Stock Ratings for OvaScience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc. and related stocks with our FREE daily email newsletter.